Elite Pharmaceuticals (ELTP)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	10.00 mm	10.00 mm	10.00 mm	10.00 mm	10.00 mm	10.00 mm
Cash burn (monthly)	(no burn)	(no burn)	3.17 mm	(no burn)	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	13.12 mm	n/a	n/a	n/a
Cash remaining	n/a	n/a	-3.12 mm	n/a	n/a	n/a
Runway (months of cash)	n/a	n/a	-1.0	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2023

ELTP institutional ownership history Ownership history

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1	0	NEW
Opened positions	1	0	NEW
Closed positions	0	1	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	7.69 mm	0.00	NEW
Total shares	82.00 k	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Fisher Asset Management	82.00 k	$7.69 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Fisher Asset Management	82.00 k	+82.00 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ELTP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Oct 24	Plassche Douglas	Common Stock	Sell	Dispose S	No	No	0.51	333,932	170.31 k	0
23 Oct 24	Plassche Douglas	Common Stock	Sell	Dispose S	No	No	0.49	800,000	392.00 k	333,932
29 Mar 24	Nasrat A Hakim	Common Stock	Grant	Acquire A	No	No	0	49,534,368	0.00	216,649,250
29 Dec 23	Nasrat A Hakim	Common Stock	Grant	Acquire A	Yes	No	0.069	2,223,147	153.40 k	2,223,147
22 Nov 23	Barry H Dash	Common Stock	Grant	Acquire A	No	No	0.0365	547,657	19.99 k	3,235,555

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)

26 Dec 24

Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB:ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced

Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets

2 Dec 24

Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB:ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that

Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse

18 Nov 24

Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB:ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information

14 Nov 24

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

7 Nov 24